12:00 AM
Nov 19, 2001
 |  BioCentury  |  Product Development

Positioning ranolazine

Biotech companies have avoided the chronic stable angina indication because it is served, albeit only moderately well, by cheap generics. But CV Therapeutics Inc. has run its clinical trials of ranolazine in a way that will allow it to both compete with the generics and work in tandem with them.

Patients with chronic stable angina have chest pain during periods of exercise or stress. The pain is due to a lack of sufficient blood flow to an area of the myocardium and may correlate with electrocardiograph changes typical of ischemia.

Therapy for chronic stable...

Read the full 463 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >